What it's for (Indications)
- Amlodipine besylate + valsartan + hydrochlorothiazide is indicated for the treatment of essential hypertension in adult patients.
- This combination therapy is specifically intended for individuals whose blood pressure is not adequately controlled by a dual-component regimen (such as amlodipine and valsartan, amlodipine and hydrochlorothiazide, or valsartan and hydrochlorothiazide).
- It may also be considered as initial therapy for patients with severe hypertension, where the likelihood of achieving blood pressure goals with a single agent is low.
- The rationale for this triple combination therapy is to leverage the complementary mechanisms of action of a calcium channel blocker, an angiotensin receptor blocker, and a thiazide diuretic, thereby providing comprehensive blood pressure reduction.
- Effective blood pressure control is crucial in reducing the risk of major cardiovascular events, including stroke, myocardial infarction, and heart failure, as well as slowing the progression of kidney disease.
- Prescribing decisions should always be individualized, considering the patient's existing therapeutic regimen, blood pressure response, and tolerability profile.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Amlodipine besylate + valsartan + hydrochlorothiazide is provided as a fixed-dose combination and is administered orally once daily. This medication is not indicated for initial therapy in patients who have not been adequately titrated on individual components. Dosage should be individualized based on the patient's prior therapy, current blood pressure control, and tolerance. The recommended starting dose often reflects the dose of the individual components the patient was previously stable on. Common starting strengths include 5 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide or 10 mg amlodipine/160 mg valsartan/12.5 mg hydrochlorothiazide. Dosage adjustments, if required, should be made gradually, typically after 2 to 4 weeks of therapy, allowing sufficient time for the full antihypertensive effect to be observed. The maximum recommended dose is 10 mg amlodipine/320 mg valsartan/25 mg hydrochlorothiazide. This medication can be taken with or without food. Special consideration should be given to patients with renal impairment (creatinine clearance <30 mL/min) or severe hepatic impairment, as dose adjustments may be necessary, or the medication may be contraindicated. |
Safety & Warnings
Common Side Effects
- The combination of amlodipine besylate + valsartan + hydrochlorothiazide can lead to a range of side effects, which may vary in incidence and severity.
- Common adverse reactions include dizziness, headache, fatigue, and peripheral edema (swelling, predominantly in the ankles and feet), the latter being particularly associated with amlodipine.
- Orthostatic hypotension, characterized by a sudden drop in blood pressure upon standing, is also a potential concern, especially with the diuretic and ARB components.
- Electrolyte imbalances, such as hypokalemia, hyponatremia, and hyperuricemia, are common with hydrochlorothiazide, necessitating regular monitoring.
- Other reported side effects include nasopharyngitis, upper respiratory tract infection, back pain, and gastrointestinal disturbances like nausea or abdominal pain.
- Less common but more serious adverse events include renal dysfunction (especially in patients with pre-existing renal impairment or volume depletion), hepatic enzyme elevations, and allergic reactions such as angioedema (swelling of the face, lips, or throat, a rare but serious effect of valsartan).
- Patients should be advised to promptly report any persistent, severe, or unusual symptoms to their healthcare provider.
- Regular monitoring of blood pressure, electrolytes, and renal function is crucial during treatment.
Serious Warnings
- Black Box Warning: The valsartan component of amlodipine besylate + valsartan + hydrochlorothiazide carries a critical Black Box Warning regarding fetal toxicity. When pregnancy is detected, amlodipine besylate + valsartan + hydrochlorothiazide must be discontinued as soon as possible. Drugs that act directly on the renin-angiotensin system (RAS), including valsartan, can cause severe injury and even death to the developing fetus when administered to pregnant women. This risk is particularly pronounced during the second and third trimesters of pregnancy due to significant impact on fetal renal development and function, potentially leading to oligohydramnios, fetal anuria, lung hypoplasia, skeletal deformations, and death. While the primary risk is associated with exposure during these later stages, limited data also suggest potential for fetal harm from first-trimester exposure. Therefore, women of childbearing potential should be made fully aware of these potential risks and counselled on the use of effective contraception. If pregnancy occurs, healthcare providers must immediately discontinue this medication and consider alternative antihypertensive treatments if medically indicated for the mother.
- Use with caution in patients with aortic stenosis, left ventricular outflow obstruction, unstable angina, or unstable heart failure following myocardial infarction, as these conditions may be exacerbated or require careful monitoring.
How it Works (Mechanism of Action)
Amlodipine is a dihydropyridine calcium channel blocker. It selectively blocks calcium ion influx into vascular smooth muscle and cardiac muscle, with greater selectivity for vascular smooth muscle. This leads to peripheral vasodilation and a reduction in peripheral vascular resistance, thereby lowering blood pressure. Amlodipine also possesses antioxidant properties and enhances the production of nitric oxide (NO), a potent vasodilator, contributing to its antihypertensive effects.
Commercial Brands (Alternatives)
Covam Plus
BrandGetz Pharma
Amlodipine besylate (10 mg ) + Valsartan ( 160 mg ) + Hydrochlorithiazide ( 25 mg)
Covam Plus
BrandGetz Pharma
Amlodipine besylate (10 mg ) + Valsartan ( 160 mg ) + Hydrochlorithiazide ( 25 mg)
Avsar Plus
BrandPharm Evo
Amlodipine besylate (10mg) + Valsartan (160mg) + Hydrochlorithiazide (25mg)